Aura Biosciences, Inc. (AURA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Aura Biosciences, Inc. (AURA) closed at USD 6.17 on 2026-10-14, a change of -3.1 % over the past year, with a market capitalization of USD 657.49M.

Aura Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Aura Biosciences, Inc. key figures

Previous close

USD 6.17 (2026-10-14)

1-year change

-3.1 %

Market cap

USD 657.49M

Enterprise value

USD 350.24M

P/E ratio (trailing)

-3.58

P/E ratio (forward)

-3.12

EPS (trailing)

-1.77

EPS (forward)

-2.03

PEG ratio

n/a

Price to book

2.08

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.87

Employees

113

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Aura Biosciences, Inc.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Aura Biosciences, Inc. and compare it with other stocks.